THERAPEUTIC AREAS

Core

Diabetes

Type 2 diabetes mellitus is a clinical syndrome, characterised by hypoglycemia. It is a growing global health problem.

China has the world’s largest diabetes epidemic1; if current trends continue, it is expected that 143 million people in China will have diabetes by 2035. It is also estimated that more than 50 million patients are undiagnosed, spurring the growth of the overall diabetes pharmaceutical market in China to expand 20% annually to reach RMB$20 billion by 2016, becoming one of the largest therapeutic areas in the China2.

With rising prevalence and an ageing population, there is a great demand for newer, safer and more cost effective Type 2 diabetes therapeutics.

 

1. International Diabetes Federation. Diabetes Atlas 7th Edition 2015.

2. Bloomberg. China diabetes triples creating a $3.2 billion drug market

Dermatology

We are focused on delivering effective and quality dermatological treatments for a wide range of skin diseases and conditions including :

- wound healing

- psoriasis

- skin allergies

Opthalmology

We are currently focused on eye diseases that can lead to loss of vision such as glaucoma, cycloplegia, mydriasis, cataract and other age-related macular degeneration.

It is estimated that 285 million people are visually impaired while 39 million people are blind worldwide1. Glaucoma is thought to be the second leading cause of blindness behind cataract and it is expected that the number of people suffering from glaucoma will increase to about 80 million by 20202.

We are constantly working to develop and commercialise therapies to treat vision-threatening diseases either in-house or through partnerships.

 

1. WHO Global Data on Visual Impairment

2. IAPB. Vision 2020.

Non - Core

Osteoporosis

Osteoporosis causes more than 8.9 million fractures worldwide annually. It is estimated to affect 200 million women worldwide1, of which the majority comprise of elderly women aged 60 and above2.

In China, osteoporosis affects almost 70 million Chinese over the age of 50 and causes about 687,000 hip fractures in China each year3.

China’s osteoporosis market is expected to be worth RMB15.5 billion in 2015 (approximately one fifth of the global osteoporosis market) and will continue to grow quickly largely due to increasing prevalence of osteoporosis among the female and elderly population, poor diet and urbanisation.

 

1.

Johnell O and Kanis JA. Osteoporosis Int 2006. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures.

2.

Kanis JA. WHO Technical Report, University of Sheffield, 2007.

3.

China Health Promotion Foundation (2008) White Paper China 2008, Osteoporosis a Summary Statement of China.

Cancer related complications

Independent studies have suggested that Erythropoiesis-stimulating agents such as EPO have demonstrated efficacy in the treatment of cancer-related anaemia. These trials have demonstrated that the use of recombinant human EPO to treat anemia in cancer patients increases haemoglobin levels, reduces transfusion requirements and improves QOL, predominantly by reducing fatigue1. Moreover, EPO therapy may also improve cognitive function in patients receiving chemotherapy2.

Invasive fungal infections are one of the leading causes of morbidity and mortality in cancer patients3.

 

1.

Clark O, Adams JR, Bennett CL et al.: Erythropoietin, uncertainty principle and cancer related anaemia. BMC Cancer 2, 23 (2002).

2.

Beutel G, Ganser A: Risks and benefits of erythropoiesis-stimulating agents in cancer management. Semin. Hematol. 44, 157–165 (2007).

3.

Viscoli C, Castagnola E, Machetti M.: Antifungal treatment in patients with cancer, J Intern Med Suppl. (1997).